SCHEMBL4339792

SCHEMBL4339792

CC(C)CN(C[C@H]1OC(C)(C)N(C(=O)O)[C@H]1Cc1ccc(O)cc1)S(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 5/20 0.38
MLNR O43193 1/20 0.36
ABCB11 O95342 1/20 0.36
LMNA P02545 1/20 0.36
CTSD P07339 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP3A5 P20815 1/20 0.36
CNR1 P21554 1/20 0.36
TBXAS1 P24557 1/20 0.36
ADRA1A P35348 1/20 0.36
RORC P51449 5/20 0.36
ABCB1 P08183 1/20 0.34
KCNE1 P15382 1/20 0.34
KCNQ1 P51787 1/20 0.34
KCNH2 Q12809 1/20 0.34
SCN5A Q14524 1/20 0.34
KCND3 Q9UK17 1/20 0.34
MMP2 P08253 2/20 0.34
MMP13 P45452 2/20 0.34
MMP14 P50281 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4344286 0.86 LMNA (0.44) TAS2R14LMNAMMP2MMP13
SCHEMBL4344331 0.86 SMN1; SMN2 (0.42) TAS2R14LMNA
SCHEMBL4347074 0.83 MAOB (0.42) MLNRABCB11LMNACTSDCYP3A4
SCHEMBL13617744 0.81 ABCB1 (0.52) MLNRABCB11LMNACTSDCYP3A4
SCHEMBL19140533 0.81 BMP1 (0.38) TAS2R14LMNAMMP2MMP13MMP14
SCHEMBL19140531 0.80 TAS2R14 (0.41) TAS2R14LMNAMMP2MMP13MMP14
SCHEMBL4340851 0.79 MMP2 (0.49) CYP3A4MMP2MMP13MMP14ADAMTS4
SCHEMBL4339790 0.78 ITGB3 (0.31)
SCHEMBL4347227 0.76 ADAMTS4 (0.46) TAS2R14LMNAABCB1MMP2MMP13
SCHEMBL13617804 0.76 MEN1 (0.41) TAS2R14LMNAABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455497-B2 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-06-04 US disclosed
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-05 US disclosed
EP-1194404-B1 INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMA (US) 2006-05-03 EP disclosed
US-6878728-B1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICAL INCORPORATED (US) 2005-04-12 US disclosed
US-20040122000-A1 Inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED. 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122000-A1 Inhibitors of aspartyl protease SPINT2, DNPEP, PRSS1 TAS2R14 2211/4885MLNR 4166/4885ABCB11 1940/4885
US-20090274650-A1 INHIBITORS OF ASPARTYL PROTEASE SPINT2, DNPEP, PRSS1 TAS2R14 2211/4885MLNR 4166/4885ABCB11 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.